about
Synthetic lethality in lung cancer and translation to clinical therapiesPhotooxygenation of an amino-thienopyridone yields a more potent PTP4A3 inhibitor.Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancerThe role of GATA2 in lethal prostate cancer aggressiveness.Targeting PTPRZ inhibits stem cell-like properties and tumorigenicity in glioblastoma cells.Induced protein degradation: an emerging drug discovery paradigm.Strategies to Inhibit Myc and Their Clinical ApplicabilityMacrocycle peptides delineate locked-open inhibition mechanism for microorganism phosphoglycerate mutases.Drugging the 'undruggable' cancer targets.Drugging RAS: Know the enemy.Targeted protein knockdown using small molecule degraders.Targeted Protein Degradation: from Chemical Biology to Drug Discovery.Surface plasmon resonance and isothermal titration calorimetry to monitor the Ni(II)-dependent binding of Helicobacter pylori NikR to DNA.Small-Molecule Screens: A Gateway to Cancer Therapeutic Agents with Case Studies of Food and Drug Administration-Approved Drugs.Integrating phosphoproteomics into the clinical management of prostate cancerIdentification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells.ATAD2 in cancer: a pharmacologically challenging but tractable target.Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.Regulatory Mechanisms and Novel Therapeutic Targeting Strategies for Protein Tyrosine Phosphatases.Dual colorimetric and fluorogenic probes for visualizing tyrosine phosphatase activity.Cutting down the time to identify challenging tumor therapeutic targets and drug combinations using synthetic lethal approaches.Classification of Complete Proteomes of Different Organisms and Protein Sets Based on Their Protein Distributions in Terms of Some Key Attributes of Proteins.New Approaches to Difficult Drug Targets: The Phosphatase StoryDiscovery of Mcl-1 inhibitors from integrated high throughput and virtual screeningOutcome analysis of Phase I trial patients with metastatic and/or mutant non-small cell lung cancerTargeted Intracellular Delivery of Antibodies: The State of the Artp21-activated kinase signalling in pancreatic cancer: New insights into tumour biology and immune modulation
P2860
Q28072904-D5493048-F06D-44E2-BD68-84B9F4F7547BQ30276629-3F80CF62-404D-4522-8BA9-366E30DE4EDAQ33779691-11651505-E158-418F-B048-6266C914EDDDQ33848134-E42F5925-F183-41C1-9580-20E0C26E55B1Q33912275-CD14ECE1-D46F-4B73-AB5E-37670F803C45Q34545841-F662B9FA-D486-4B40-94A2-C93C054B4CD1Q36303678-E258BB9A-9410-4487-817D-1F192A3775EFQ36331476-7EA4E5C5-E86A-43F9-B4D0-84E932BC690BQ38667658-908636D7-5990-407F-92DF-1D830A59953FQ39182842-67F4B093-F8F8-4851-9D15-6E5D08607776Q39367115-ECF481F8-66D7-4FD8-AC62-2A36E9290FC1Q39396984-027936ED-64FB-408B-B16A-54252991D2CEQ39435560-4B9A09D1-2061-45EE-9B31-A2C1BDC896A8Q42116442-84F7C044-2B46-4C43-96F2-34FC41D64DDDQ42321511-FDD65C77-5246-4582-BDC2-EC2A98C132D1Q47155582-E483324F-BE35-40B5-BBD2-48B5E87CEE90Q47392240-5FA88446-1732-404B-A159-20270D7898A0Q47411643-2DD9631A-1FA8-4DBB-8EA3-2A7D83B7EBC2Q48103763-90DF1B06-D139-461D-935D-97C4FD22AD46Q48291562-4FC53676-AFB3-4D87-A727-5E32E3DAD13FQ52641490-4CC1BA53-9D7C-4C40-BAAE-3E3F96B64DF1Q55025251-7998C285-3620-4BC8-8F6E-E67275FD276AQ56513340-E7F04B4F-7947-43F1-AD79-3D860B6EA8F9Q56811078-2297186F-D47C-4644-B869-2BA5E4CC505AQ57117154-B17E47F1-3202-4361-8199-9E18C5E0C63DQ58566968-0B3B5CAB-86CC-4DCF-9B81-0D91776B153FQ58760423-25FA4973-88EA-4219-855E-21AE9ACE8C4B
P2860
description
2015 nî lūn-bûn
@nan
2015 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Drugging Undruggable Molecular Cancer Targets.
@ast
Drugging Undruggable Molecular Cancer Targets.
@en
type
label
Drugging Undruggable Molecular Cancer Targets.
@ast
Drugging Undruggable Molecular Cancer Targets.
@en
prefLabel
Drugging Undruggable Molecular Cancer Targets.
@ast
Drugging Undruggable Molecular Cancer Targets.
@en
P1476
Drugging Undruggable Molecular Cancer Targets.
@en
P356
10.1146/ANNUREV-PHARMTOX-010715-103440
P577
2015-11-02T00:00:00Z